

Is the Erythrocyte Membrane Fatty Acid Composition a Valid Index of Skeletal Muscle Membrane Fatty Acid Composition?

Lucrezia Di Marino, Ada Maffettone, Paola Cipriano, Maurizio Sacco, Roberto Di Palma, Bruno Amato, Gennaro Quarto, Gabriele Riccardi, and Angela Albarosa Rivellese

Recent studies suggest that insulin sensitivity is related to the fatty acid composition of phospholipids in skeletal muscle (SM) membranes. Since it is difficult to obtain muscle biopsies, it may be useful to have information on the fatty acid composition using more accessible cells such as erythrocytes. This would be possible only if the composition of erythrocyte and muscle membranes are very similar. Since no comparative data are available, we evaluated the phospholipid fatty acid composition of erythrocyte and SM membranes in 16 individuals, 10 nondiabetics (male to female ratio, 4:6; age, 50 ± 11 years; body mass index, 27 ± 5 kg/m²; mean \pm SD) and 6 type 2 diabetic patients (male to female ratio, 2:4; age, 64 ± 5 years; body mass index, 27 ± 4 kg/m²). All patients underwent abdominal surgery, during which a biopsy of the abdominal rectus muscle (50 to 100 mg) was obtained. Erythrocyte and SM phospholipid fatty acids were extracted and then methylated; the methyl fatty acids were separated and quantified by gas chromatography. Compared with erythrocyte membranes, muscle membranes showed a significantly higher proportion of ω -6 polyunsaturated fatty acid ([PUFA] $43.0\% \pm 3.1\%$ v $29.7\% \pm 1.6\%$, $P < .001$) and lower saturated fatty acid ([SFA] $41.1\% \pm 1.5\%$ v $43.4\% \pm 1.2\%$, $P < .001$), monounsaturated fatty acid ([MUFA] $11.5\% \pm 1.7\%$ v $20.0\% \pm 1.9\%$, $P < .001$), and ω -3 PUFA ($3.8\% \pm 0.6\%$ v $7.4\% \pm 1.0\%$, $P < .001$). The greatest increase involved linoleic acid ($26.9\% \pm 2.8\%$ v $10.3\% \pm 1.6\%$, $P < .001$), whereas lignoceric acid ($0.8\% \pm 0.2\%$ v $5.0\% \pm 0.6\%$, $P < .001$) and oleic acid ($10.4\% \pm 1.6\%$ v $13.5\% \pm 1.3\%$, $P < .001$) were significantly lower. These results show that erythrocyte and muscle membrane phospholipid fatty acids are significantly different. Therefore, data on SM membranes cannot be extrapolated on the basis of measures of erythrocyte phospholipid fatty acid composition.

Copyright © 2000 by W.B. Saunders Company

RECENT STUDIES indicate that peripheral insulin sensitivity can be influenced by the dietary fatty acid composition and consequently by the phospholipid fatty acid composition of skeletal muscle (SM) membranes. Studies in rats¹ have shown that a diet rich in ω -3 polyunsaturated fatty acids (PUFA) has a beneficial effect on insulin resistance and that insulin sensitivity is strongly related to the proportion of SM phospholipid long-chain ω -3 fatty acids. The few studies in humans have shown, on one hand, a positive relationship between insulin sensitivity and the percentage of phospholipid long-chain PUFA in SM membranes^{2,3} and, on the other hand, an inverse relationship with the percentage of saturated fatty acids (SFA).^{2,4}

Since cellular membrane fatty acids are derived from the plasma pool of fatty acids—which itself derives mainly from dietary fats—it may be hypothesized that all cellular membranes have a similar fatty acid composition. Since it is difficult to obtain SM specimens, it would be easier to study more accessible cells such as red blood cells (RBCs). This hypothesis must be validated by comparative data, which are not currently available. Therefore, the aim of this study was to compare the membrane fatty acid composition of SM and RBCs. As a secondary aim, we also tried to verify whether the SM membrane fatty acid composition is related to indices of insulin sensitivity, as previously reported.²⁻⁴

From the Department of Clinical and Experimental Medicine, Fourth Division of General Surgery, Emergency Unit, Seventh Division of General Surgery, and Second Division of General Surgery, Federico II University Medical School, Naples, Italy.

Submitted October 7, 1999; accepted March 10, 2000.

Reprint requests to Lucrezia Di Marino, DSc, Department of Clinical and Experimental Medicine, Federico II University Medical School, Via Sergio Pansini 5-80131 Naples, Italy.

Copyright © 2000 by W.B. Saunders Company

0026-0495/00/4909-0016\$10.00/0

doi:10.1053/meta.2000.8616

SUBJECTS AND METHODS

Patients

After provision of informed consent, 16 subjects (10 nondiabetics and 6 type 2 diabetic patients according to the World Health Organization classification)⁵ requiring abdominal surgery participated in the study. Patients with neoplasms, cachexia, severe infection, jaundice, or severe cardiovascular disease were excluded from the study. Diabetic subjects were treated with diet alone ($n = 2$) or diet plus glucose-lowering medications ($n = 4$) and were in good metabolic control. The protocol was approved by the Ethics Committee of Federico II University (Naples, Italy).

Biological Samples

The day before surgery, fasting blood samples were collected to evaluate serum cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol, plasma glucose and insulin, and erythrocyte fatty acid composition. During surgery, specimens (50 to 100 mg) of the abdominal rectus muscle were also obtained from each subject. Packed RBCs, obtained from EDTA-K₃ venous blood samples after isolating the plasma and buffy coat, were immediately frozen at -80°C after addition of 5 $\mu\text{L/mL}$ butylated hydroxytoluene 2% (BHT) in methanol (wt/vol) + N₂.⁶ Skeletal muscle samples were washed in a saline solution and immediately stored in N₂ at -80°C until analysis.

Assays

Serum total cholesterol and triglycerides were analyzed on a Cobas Mira (Roche, Basel, Switzerland) analyzer with enzymatic colorimetric methods using commercially available kits (Boehringer, Mannheim, Germany).^{7,8} HDL cholesterol was evaluated after precipitation of all other lipoprotein classes with phosphotungstate sodium and magnesium chloride.⁹ Blood glucose was evaluated with the enzymatic glucose-hexokinase method (Roche).¹⁰ Insulin was evaluated using a radioimmuno-logic method (Technogenetics, Milan, Italy).¹¹

Membrane phospholipid fatty acid. Specimens of muscle (30 to 50 mg) were homogenated in a chloroform:methanol (2:1 vol/vol) and BHT 0.01% (wt/vol) ice-cold solution, and total lipids were extracted by the Folch procedure.¹² Phospholipids were then isolated by thin-layer chromatography.¹³ Two hundred microliters of RBCs were

hemolyzed with distilled water, and total lipids were extracted with the same procedure as for muscle samples. Both muscle and erythrocyte phospholipids were transmethylated with 1 mL benzene and 5 mL 2% H₂SO₄ in methanol at 65° to 70°C for 18 hours¹⁴; the fatty acid methyl esters (FAMES) were then extracted with *n*-hexane.

Both muscle and erythrocyte FAMES were separated and measured on a Hewlett-Packard (Palo Alto, CA) 5890 gas chromatograph equipped with a 30-m Omegawax 320 capillary column (Supelco, Bellefonte, PA). Dried helium was used as a carrier gas (linear velocity, 24 cm/s; split ratio, RBCs 30:1 and SM 5:1). The initial column temperature was 200°C for 18 minutes and the increase rate was 1°C/min until 215°C for 10 minutes. The temperature was 250°C at the injection port and 260°C at the hydrogen flame ionization detector. Fatty acids were identified by comparing their retention times against those of the Supelco standard mixtures (PUFA, GLC 1100, and rapeseed oil).

All RBC and SM samples were examined in triplicate. A coefficient of variation (CV) less than 3% was accepted for fatty acids at concentrations greater than 5%; for lower concentrations (<5% and <1%), a CV less than 5% and less than 10%, respectively, was accepted.

Statistical Analysis

Results for fatty acids are expressed as a percentage of total fatty acids. Differences between SM and erythrocytes were evaluated using the *t* test for paired data.¹⁵ Furthermore, linear regression analysis was used to evaluate the possible relationship between muscle fatty acids and insulin resistance, evaluated as both fasting serum insulin and homeostasis model assessment (HOMA).¹⁶

RESULTS

The clinical characteristics of the subjects are shown in Table 1. There were no significant differences in the 2 groups, although diabetic patients tended to be older and to have higher serum cholesterol, triglycerides, and plasma glucose. All data concerning SM and RBC fatty acid composition for diabetic and nondiabetic patients were completely superimposable, and they were therefore considered as 1 group. The content of total SFA was higher in RBCs versus SM cells (43.4% ± 1.2% *v* 41.1% ± 1.5%, *P* < .001; Table 2). This was mostly due to an increase in long-chain SFA (behenic and lignoceric acid). Total monounsaturated fatty acids (MUFAs) were higher in RBCs than in SM cells (20.0% ± 1.9% *v* 11.5% ± 1.7%, *P* < .001); the increase involving mainly oleic and nervonic acid (Table 2). Total ω-3 PUFAs were significantly higher in RBCs versus SM cells (7.4% ± 1.0% *v* 3.8% ± 0.6%, *P* < .001) due to significant enrichment in long-chain fatty acids (docosapentaenoic and docosahexaenoic acid).

A significant reduction of ω-6 PUFA was found in RBCs compared with SM cells (29.7% ± 1.6% *v* 43.0% ± 3.1%, *P* < .001), which is mostly accounted for by significantly lower

Table 2. Fatty Acid Composition of RBCs and SM Cells
(%, mean ± SD)

Fatty Acid	RBCs	SM Cells
Palmitic acid C16:0	22.5 ± 1.0	22.7 ± 1.4
Stearic acid C18:0	13.4 ± 0.8	16.3 ± 1.6*
Behenic acid C22:0	1.9 ± 0.2	0.7 ± 0.1*
Lignoceric acid C24:0	5.0 ± 0.6	0.8 ± 0.2*
Total SFA	43.4 ± 1.2	41.1 ± 1.5*
Palmitoleic acid C16:1 ω-7	0.7 ± 0.2	1.0 ± 0.2*
Oleic acid C18:1 ω-9	13.5 ± 1.3	10.4 ± 1.6*
Nervonic acid C24:1 ω-9	5.5 ± 1.0	NF*
Total MUFA	20.0 ± 1.9	11.5 ± 1.7*
Linoleic acid C18:2 ω-6	10.3 ± 1.6	26.9 ± 2.8*
Arachidonic acid C20:4 ω-6	14.1 ± 1.0	12.7 ± 2.0†
Docosatetraenoic acid C22:4 ω-6	2.8 ± 0.6	0.9 ± 0.2*
Docosapentaenoic acid C22:5 ω-6	0.4 ± 0.1	0.3 ± 0.1*
Total PUFA ω-6	29.7 ± 1.6	43.0 ± 3.1*
Eicosapentaenoic acid C20:5 ω-3	0.5 ± 0.2	0.5 ± 0.1
Docosapentaenoic acid C22:5 ω-3	1.6 ± 0.2	1.2 ± 0.2*
Docosahexaenoic acid C22:6 ω-3	5.2 ± 0.9	1.9 ± 0.6*
Total PUFA ω-3	7.4 ± 1.0	3.8 ± 0.6*

Abbreviation: NF, not found.

**P* < .001, †*P* < .01, SM *v* RBCs.

concentrations of linoleic acid (10.3% ± 1.6% *v* 26.9% ± 2.8%, *P* < .001). Also for this class of fatty acids, RBCs are characterized by higher concentrations of long-chain fatty acids (docosatetraenoic and docosapentaenoic acid) compared with SM cells.

There were no significant correlations between the percentage of fatty acids largely present in SM and insulin resistance evaluated as fasting insulin and as HOMA, both in the study population as a whole (Table 3) and in the 2 groups (diabetic and nondiabetic patients) considered separately (data not shown).

DISCUSSION

This study clearly demonstrates that the fatty acid composition of RBC and SM membrane phospholipids is significantly different. The former are characterized by significantly lower concentrations of ω-6 PUFAs, mainly due to a reduction of linoleic acid by almost one third. On the other hand, compared with SM,

Table 3. Simple Linear Correlations (*r*) Between SM Fatty Acids and Indices of Insulin Resistance

SM Fatty Acid	Fasting Serum Insulin	HOMA
SFA	-.011	.030
C16:0	.045	-.042
C18:0	-.004	.124
MUFA	-.065	.093
C16:1 ω-7	.093	.150
C18:1 ω-9	-.077	.082
ω-6 PUFA	.008	-.080
C18:2	.108	-.064
C20:3	.384	.396
C20:4	-.236	-.153
C22:4	.167	.260
C22:5	.136	.168
ω-3 PUFA	-.054	-.104
C20:5	-.030	-.031
C22:5	.177	.181
C22:6	-.106	-.160

Table 1. Characteristics of the Participants (mean ± SD)

Characteristic	Controls	Type 2 Diabetics
No. of subjects	10	6
Male/female ratio	4/6	2/4
Age (yr)	50 ± 11	64 ± 5
BMI (kg/m ²)	27 ± 5	27 ± 4
Fasting plasma glucose (mmol/L)	5.5 ± 1.1	6.7 ± 1.8
Plasma insulin (μU/mL)	8 ± 3	10 ± 5
Serum cholesterol (mmol/L)	5.3 ± 1.6	6.4 ± 1.0
Serum triglycerides (mmol/L)	1.5 ± 0.7	1.9 ± 1.1
HDL cholesterol (mmol/L)	1.1 ± 0.3	1.1 ± 0.2

RBC membranes have a higher concentration of long-chain fatty acids (>18C) in SFA, MUFA, and ω -3 or ω -6, PUFA.

Since the fatty acids of different membranes of the body are derived from the same pool of fatty acids, ie, plasma—which itself derives mainly from dietary fats—the clear differences in the fatty acid composition of RBCs and SM cells found in this study were unexpected. These data imply that the uptake of fatty acids from the plasma pool is specific for different tissue types and depends on their function. Recently, it has been shown that there are different families of fatty acid-binding proteins in humans, with differing ability to bind fatty acids. More specifically, it has been shown that the fatty acid-binding protein in muscles is able to bind a greater amount of some fatty acids, including linoleic acid, compared with the same protein of hepatic origin.^{17,18} These differences could explain the increased content of linoleic acid in SM in our study.

Moreover, the differences in fatty acid composition between RBCs and SM cells may also be due, at least in part, to the different phospholipid composition of these 2 types of cells. In fact, RBCs are richer in sphingomyelin, which preferentially esterifies long-chain fatty acids, while SM cells are richer in cardiolipin, which instead preferentially esterifies linoleic acid.¹⁹⁻²¹

Whatever the explanation for the variations between RBC and SM fatty acids, our results clearly demonstrate many differences in RBC and SM fatty acid composition, and thus, SM membrane composition cannot be studied using the more accessible RBCs. This conclusion may be less valid for 2 fatty acids, palmitic and eicosapentaenoic, whose content is very

similar in RBCs and SM. Therefore, RBC composition may be considered a satisfactory index of SM composition only for these 2 fatty acids.

Concerning the secondary aim of the study, we did not observe any relation between SM fatty acids and indices of insulin resistance (both fasting plasma insulin and HOMA). This result is in disagreement with the few data in the literature. As a matter of fact, other studies show an inverse relationship between the percentage of palmitic acid in the SM and insulin sensitivity in the elderly.⁴ Furthermore, they show a direct correlation between insulin sensitivity and the percentage of PUFAs in the muscle of both normal and insulin-resistant subjects (affected by coronary heart disease).²

Such differences could be due to the fact that the relation between SFA and PUFA and insulin sensitivity may be evident only in populations with a high dietary intake of these fatty acids. In our population, the dietary intake of both SFA and PUFA is lower versus Australian and Scandinavian populations.²² Therefore, at least at these low levels, SFA and PUFA may not be important for the regulation of insulin action. However, it would be important to study a larger number of people with a much more variable fatty acid intake.

In conclusion, our study clearly demonstrates that the RBC membrane fatty acid composition is not a valid index of the fatty acid composition of SM membranes. Therefore, further studies to evaluate the possible relationship between membrane composition and insulin action should use SM cells directly.

REFERENCES

1. Storlien LH, Jenkins AB, Chisholm DJ, et al: Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω -3 fatty acids in muscle phospholipid. *Diabetes* 40:280-289, 1991
2. Borkman M, Storlien LH, Pan DA, et al: The relation between insulin sensitivity and the fatty acid composition of skeletal muscle phospholipids. *N Engl J Med* 328:238-244, 1993
3. Pan DA, Lillioja S, Milner MR, et al: Skeletal muscle membrane lipid composition is related to adiposity and insulin action. *J Clin Invest* 96:2802-2808, 1995
4. Vessby B, Tengblad S, Lithell H: Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. *Diabetologia* 37:1044-1050, 1994
5. World Health Organization Expert Committee on Diabetes Mellitus: Second report. *World Health Org Tech Rep Ser* 646:7-14, 1980
6. Ways P, Reed CF, Hanahan DJ: Red-cell and plasma lipids in acanthocytosis. *J Clin Invest* 42:1248-1260, 1963
7. Siedel J, Schlumberger H, Klose S, et al: Improved reagent for enzymatic determination of serum cholesterol. *J Clin Chem Clin Biochem* 19:838-839, 1981
8. Wahlefeld AW: Triglycerides determination after enzymatic hydrolysis, in Bergmeyer HU (ed): *Methods of Enzymatic Analysis*, vol 4 (ed 2). London, UK, Weinheim Academic Press, 1974
9. Lopes-Virella MF, Stone P, Ellis S, et al: Cholesterol determination in high-density lipoprotein separated by three different methods. *Clin Chem* 23:882-884, 1977
10. Bondar RJL, Mead DC: Evaluation of glucose-6-phosphate dehydrogenase from *Leuconostoc mesenteroides* in the hexokinase method for determining glucose in serum. *Clin Chem* 20:586-590, 1974
11. Gennaro WD, Van Norman JD: Quantitation of free, total and antibody bound insulin in insulin treated diabetics. *Clin Chem* 27:873-879, 1975
12. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* 226:497-509, 1957
13. Boberg J: Separation of labeled plasma and tissue lipids by thin layer chromatography. A quantitative methodological study. *Clin Chim Acta* 14:325-334, 1966
14. Sheppard AJ, Iverson JL: Esterification of fatty acids for gas-liquid chromatographic analysis. *J Chromatogr Sci* 13:448-452, 1975
15. Snedecor GV, Cochran WG: *Statistical Methods* (ed 7). Ames, IA, Iowa State University Press, 1980, pp 91-116, 172-198
16. Mathews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412-419, 1985
17. Peeters RA, Ena JM, Veerkamp JH: Expression in *Escherichia coli* and characterization of the fatty-acid-binding protein from human muscle. *Biochem J* 278:361-364, 1991
18. Maatman RG, Van Moerkerk HTB, Nooren IMA, et al: Expression of human liver fatty acid-binding protein in *Escherichia coli* and comparative analysis of its binding characteristics with muscle fatty acid-binding protein. *Biochim Biophys Acta* 1214:1-10, 1994
19. Devlin TM: *Manuale di biochimica con aspetti clinici*. Padova, Italy, Liviana Università, 1989, pp 196-209
20. Ways P, Hanahan DJ: Characterization and quantification of red cell lipids in normal man. *J Lipid Res* 5:318-328, 1964
21. Bruce A: Skeletal muscle lipids. III. Changes in fatty acid composition of individual phosphoglycerides in man from fetal to middle age. *J Lipid Res* 15:109-113, 1974
22. Giacco R, Riccardi G: Comparison of current eating habits in various Mediterranean countries, in Spiller GA (ed): *The Mediterranean Diets in Health and Disease*. New York, NY, Van Nostrand Reinhold, 1991, pp 3-9